HCPLive

HCPLive HCPLive.com is your one-stop shop for healthcare news, medical conference coverage, and more. Clinical News for Connected Physicians

Advancing Alzheimer Disease Care Through Early Diagnosis and CollaborationGayatri Devi, MD, MS, FACP, FAAN, and Ronald P...
10/30/2025

Advancing Alzheimer Disease Care Through Early Diagnosis and Collaboration

Gayatri Devi, MD, MS, FACP, FAAN, and Ronald Primas, MD, FACP, FACPM, DABIHM, CTH, explore how early diagnosis of Alzheimer disease and the proactive involvement of frontline clinicians are essential to timely identification and implementation of best practices for optimal patient care. The discussion highlights the evolving understanding of Alzheimer disease pathophysiology and emerging treatment options, emphasizing the growing importance of early detection and intervention. They examine risk factors and the critical role of biomarkers in accurately diagnosing and staging the disease, particularly in frontline care settings where clinicians often have the first opportunity to recognize subtle cognitive changes.

By leveraging patient trust and strengthening communication, clinicians can more effectively guide patients and families through diagnosis, referrals to neurologists, and consideration of disease-modifying therapies. The conversation also underscores the need for multidisciplinary collaboration in managing amyloid-related imaging abnormalities and other complexities of treatment.

Together, these insights reflect a shared commitment to improving outcomes and advancing the standard of care for individuals living with Alzheimer disease.

Watch Now: https://hubs.li/Q03QWh8N0

Learn how simplifying the standard of care can make a difference for HCV. Experts Patrick Horne, APRN, and Tatyana Kushn...
10/29/2025

Learn how simplifying the standard of care can make a difference
for HCV. Experts Patrick Horne, APRN, and Tatyana Kushner, MD, will discuss the impact of HCV, explore nontraditional care models, and review strategies to shorten the time from diagnosis to treatment. Watch Now. bit.ly/48U1NRl

In this   article, Dr. Christopher Gomez discusses his experience diagnosing people living with Friedreich ataxia (FA), ...
10/29/2025

In this article, Dr. Christopher Gomez discusses his experience diagnosing people living with Friedreich ataxia (FA), a rare neurodegenera­tive disease. FA is the most common inherited ataxia but is not well known among the physician community. Learn more: bit.ly/4oCy8Rc

Discover how emerging therapies like aprocitentan can help manage resistant hypertension in patients with comorbid condi...
10/29/2025

Discover how emerging therapies like aprocitentan can help manage resistant hypertension in patients with comorbid conditions like chronic kidney disease. Accurate diagnosis and optimized treatment are key to improving outcomes.

Watch Now: https://hubs.li/Q03s23mQ0

10/28/2025

Have you seen our latest interview on-site at the Dermatology Conference in Las Vegas?🎥

🔗View: https://hubs.li/Q03QB78Y0

If not, check out the video to hear from Dr. Donna Culton, of UNC School of Medicine, who touched on several key takeaways regarding making an accurate and early diagnosis of .💡

The HCPLive team is here in Las Vegas at the   dermatology meeting.Interviews with leading experts, session coverage, an...
10/25/2025

The HCPLive team is here in Las Vegas at the dermatology meeting.

Interviews with leading experts, session coverage, and highlights of new data are all a part of this important meeting. Don't miss out...

View updates: https://hubs.li/Q03Q7NrV0

Childhood sugar intake may have a direct effect on cardiovascular diseases later in life, according to recent research. ...
10/25/2025

Childhood sugar intake may have a direct effect on cardiovascular diseases later in life, according to recent research. Between heart failure, stroke, and heart attack, reducing in-utero and adolescent sugar could lead to a variety of complications.

Read more: https://hubs.li/Q03Q678X0

HCPLive spoke with Eduardo Mysler, MD, about the first definitive evidence informing sequencing after failing a first TN...
10/25/2025

HCPLive spoke with Eduardo Mysler, MD, about the first definitive evidence informing sequencing after failing a first TNF inhibitor in patients with rheumatoid arthritis. Watch now: https://hubs.li/Q03Q67Zc0

10/25/2025

Stay ahead of the curve with our weekly roundup, featuring 5 key developments in healthcare—regulatory updates, treatment breakthroughs, and innovations shaping the future of medicine.

🫘FDA Approves Obinutuzumab for Lupus Nephritis: The Agency approved Genentech’s obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients, based on data from the phase 2 NOBILITY and phase 3 REGENCY studies.

🫀FDA Approves Oral Semaglutide for CV Risk Reduction in Type 2 Diabetes: The FDA approved Novo Nordisk’s oral semaglutide 7 mg and 14 mg (Rybelsus) for cardiovascular risk reduction in patients with type 2 diabetes who are at high risk, irrespective of prior CV events, based on positive results from the phase 3b SOUL trial.

👁️FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus: The Agency approved Glaukos Corporation’s Epioxa, an incision-free alternative to cross-linking procedures, to treat adult patients with keratoconus, based on results from 2 prospective, randomized, multicenter, double-masked, phase 3 trials.

📄ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance: A position paper from the American College of Physicians endorses 1 of 5 currently available performance measures for colorectal cancer screening and surveillance, informing physicians, payers, and policymakers in their selection and use of performance measures.

😴SynAIRgy: Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden: New 26-week data from the phase 3 SynAIRgy trial presented during late-breaking data sessions at the American College of Chest Physicians 2025 Annual Meeting highlight significant improvement to apnea-hypopnea index scores among patients with OSA treated with combination aroxybutynin and atomoxetine (AD109), with findings consistent across multiple weight classes.

Learn more: https://www.hcplive.com/view/the-hcpfive-top-news-for-healthcare-providers-from-the-week-of-10-19

Stay ahead of the curve with our weekly roundup, featuring 5 key developments in healthcare—regulatory updates, treatmen...
10/25/2025

Stay ahead of the curve with our weekly roundup, featuring 5 key developments in healthcare—regulatory updates, treatment breakthroughs, and innovations shaping the future of medicine.

🫘FDA Approves Obinutuzumab for Lupus Nephritis: The Agency approved Genentech’s obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients, based on data from the phase 2 NOBILITY and phase 3 REGENCY studies.

🫀FDA Approves Oral Semaglutide for CV Risk Reduction in Type 2 Diabetes: The FDA approved Novo Nordisk’s oral semaglutide 7 mg and 14 mg (Rybelsus) for cardiovascular risk reduction in patients with type 2 diabetes who are at high risk, irrespective of prior CV events, based on positive results from the phase 3b SOUL trial.

👁️FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus: The Agency approved Glaukos Corporation’s Epioxa, an incision-free alternative to cross-linking procedures, to treat adult patients with keratoconus, based on results from 2 prospective, randomized, multicenter, double-masked, phase 3 trials.

📄ACP Releases Position Paper on Colorectal Cancer Screening, Surveillance: A position paper from the American College of Physicians endorses 1 of 5 currently available performance measures for colorectal cancer screening and surveillance, informing physicians, payers, and policymakers in their selection and use of performance measures.

😴SynAIRgy: Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden: New 26-week data from the phase 3 SynAIRgy trial presented during late-breaking data sessions at the American College of Chest Physicians 2025 Annual Meeting highlight significant improvement to apnea-hypopnea index scores among patients with OSA treated with combination aroxybutynin and atomoxetine (AD109), with findings consistent across multiple weight classes.

Learn more: https://www.hcplive.com/view/the-hcpfive-top-news-for-healthcare-providers-from-the-week-of-10-19

New research reveals findings about ERCP complications in advanced CKD. While aCKD increases the risk of ERCP-related co...
10/25/2025

New research reveals findings about ERCP complications in advanced CKD. While aCKD increases the risk of ERCP-related complications overall, the odds of post-ERCP pancreatitis (PEP) were comparable to controls, suggesting the perceived elevated PEP risk may be overstated.
Read more: https://hubs.li/Q03Q680W0

Address

2 Clarke Drive
Cranbury, NJ
08512

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Alerts

Be the first to know and let us send you an email when HCPLive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to HCPLive:

Share